HCA Healthcare (HCA) Stock Forecast & Price Target

HCA Healthcare demonstrated strong financial flexibility with $1.04 billion in cash and $5.78 billion in available credit, alongside an increased dividend of 8.3% to $0.78 per share, indicating robust cash flow and commitment to returning value to shareholders. The company anticipates solid EBITDA growth of 7.6% at the mid-point, with strong management contributing to improved EBITDA margins of 21.1%, which exceeded expectations by 60 basis points. With steady same-store volume growth and increased capital expenditures aimed at expanding inpatient capacity and outpatient facilities, HCA is well-positioned for continued growth in existing markets.

HCA Healthcare is facing significant financial headwinds, highlighted by a decline in same-store revenue per adjusted admission, which came in at +2.9%, falling short of expectations and consensus estimates. Additionally, the company anticipates a notable drop in Medicaid supplemental payment revenues, projecting a decrease of $250 million to $450 million for 2026, driven by various factors including program pauses and the recurrence of earlier non-recurring payments. Furthermore, a projected 30% decline in utilization among uninsured patients indicates a concerning trend that could adversely affect the company's overall service volume and revenue generation.